Terapija muptiple skleroze - od konvencionalnih lijekova i monoklonskih protutijela do kanabinoida

Stručni rad - Stručni rad

• Autor: Zrinka Rajić Džolić
• Autor: Sara Šipicki
• Autor: Ivana Perković
• Autorova ustanova: Sveučilište u Zagrebu; Farmaceutsko-biokemijski fakultet; (Zavod za farmaceutsku kemiju)
• Znanstveno / umjetničko područje, polje i grana: BIOMEDICINA I ZDRAVSTVO; Farmacija; Farmacija

Sažetak (hrvatski)

Multiple sclerosis is an autoimmune neurodegenerative disease, with inflammation
and demyelination in the central nervous system, which results in different neurological
symptoms. TI1e disease is usually diagnosed as a relapsing-remittent multiple
sclerosis (85 %), which is characterized by acute attacks followed by recovery.
Here we describe drugs used in the therapy/management of multiple sclerosis.
In the acute phase new symptoms appear or the current neurological status worsens.
The standard therapy consists of high doses of methylprednizolone, which is efficacious
and usually leads to a quick recovery. Disease-modifying drugs are used to reduce
the frequency of relapses and to slow the progression of disability. The classical first
line drugs are interferon-P and glatiramer acetate. Other drugs include fingolimod,
teriflunomid, dimethylfumarate, mitoxantron, natalizumab, alemtuzumab and daclizumab.
Immunosupressive agents are also used in the therapy. The third class of drugs
are used to alleviate the symptoms of the disease. Here we describe the benefitial
effects of cannabinoids in more detail.

• Ključne riječi (hrvatski): multipla skleroza; monoklonska protutijela; imunosupresivi; kanabinoidi
• Jezik: hrvatski
• Vrsta publikacije: Stručni rad - Stručni rad
• Status objave: Objavljen
• Vrsta recenzije: Recenziran - domaća recenzija
• Verzija publikacije: Objavljena verzija rada (izdavačev PDF)
• Naslov časopisa: Farmaceutski glasnik
• Brojčani podaci: vol. 73, br. 3, str. 177-190
• p-ISSN: 0014-8202
• URN:NBN: urn:nbn:hr:163:783947
• Datum objave publikacije: 2017
• Vrsta resursa: Tekst
• Prava pristupa: Otvoreni pristup
• Datum i vrijeme pohrane: 2020-06-17 08:43:35